Login / Signup

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.

Yinghong ZhaiXiaofei YeFangyuan HuJinfang XuXiaojing GuoYonglong ZhuangJia He
Published in: Journal for immunotherapy of cancer (2019)
Our pharmacovigilance analysis shows a high reporting frequency of endocrine AEs provoked by ICI monotherapy (especially anti-CTLA-4 therapy) and further reinforced by combination therapy. In addition, treatment with different ICI immunotherapies may result in a unique and distinct profile of endocrinopathies. Early recognition and management of ICI-related endocrine irAEs is of vital importance in clinical practice.
Keyphrases
  • combination therapy
  • adverse drug
  • drug administration
  • clinical practice
  • oxidative stress
  • drug induced
  • randomized controlled trial
  • clinical trial
  • mesenchymal stem cells
  • climate change
  • double blind